Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. (Q48200009)

9 February 2018

title

Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. (English)

1 reference

9 February 2018

inflammatory bowel diseases

main subject

0 references

8

Warren Taylor

1 reference

9 February 2018

author name string

Sara Horst

1

1 reference

9 February 2018

Andrew Chao

2

1 reference

9 February 2018

Michael Rosen

3

1 reference

9 February 2018

Anne Nohl

4

1 reference

9 February 2018

Caroline Duley

5

1 reference

9 February 2018

Julianne H Wagnon

6

1 reference

9 February 2018

Dawn B Beaulieu

7

1 reference

9 February 2018

Lawrence Gaines

9

1 reference

9 February 2018

David A Schwartz

10

1 reference

9 February 2018

publication date

2 October 2014

1 reference

9 February 2018

Digestive Diseases and Sciences

published in

1 reference

9 February 2018

volume

60

1 reference

9 February 2018

issue

2

1 reference

9 February 2018

page(s)

465-470

1 reference

9 February 2018

https://scigraph.springernature.com/pub.10.1007/s10620-014-3375-0

exact match

0 references

cites work

Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Depression and anxiety in people with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Increased risks of developing anxiety and depression in young patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

A prospective study of the relationship between disease activity and psychologic distress in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Brain-gut interactions in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Infliximab improves quality of life in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

A simple clinical colitis activity index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

The PHQ-9: validity of a brief depression severity measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-014-3375-0

Depression screening: a practical strategy.

21 January 2018

1 reference

12 December 2020

The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial

1 reference

12 December 2020

Psychological distress, social support, and disease activity in patients with inflammatory bowel disease

1 reference

12 December 2020

Stressful life events as a risk factor for inflammatory bowel disease onset: A population-based case-control study

1 reference

12 December 2020

Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study.

1 reference

12 December 2020

10.1007/S10620-014-3375-0

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

25274158

1 reference

9 February 2018